Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
Growth Opportunities and Innovative Use Cases for AI in Clinical Trials 2022: Remote Recruitment to Expand Patient Diversity for Cancer Trials | ||
By: PR Newswire Association LLC. - 27 Jan 2023 | Back to overview list |
|
DUBLIN, Jan. 27, 2023 /PRNewswire/ -- The "Growth Opportunities and Innovative Use Cases for AI in Clinical Trials" report has been added to ResearchAndMarkets.com's offering.
Incorporating integrated AI-driven solutions in clinical trial design and patient retention will ease the go-to-market strategy for various CROs and pharma players as they will reduce costs, increase efficiency, and support the transition to decentralized trials by means of remote patient recruitment, management, as well as engagement through interactive platforms thus ensuring higher retention. Additionally, these platforms are highly beneficial in the selection of appropriate investigators and trial sites. Randomized control trials (RCTs) are another possible application for sponsors to leverage AI in analyzing vast site-level datasets for greater insight into trial design and implementation. Leading CROs such as Syneos Health or IQVIA, as well as several pharmaceutical companies such as BMS, have successfully deployed AI-based platforms to support site selection and patient recruitment. Companies (including AstraZeneca and Novartis among others) are also applying AI in clinical trials to enable the optimization of different stages with the intent of reducing the overall trial timelines. AI technologies bring fundamental innovations for transforming clinical trials, such as collecting and analyzing real-world data, seamlessly combining phases I and II of clinical trials, and developing novel patient-centered endpoints. AI can be leveraged to create standardized, structured, and digital data elements from a range of inputs, and as AI-enabled study design helps optimize and accelerate the creation of patient-centric designs, it significantly reduces patient burden, increases the likelihood of success, decreases the number of amendments, and improves the overall efficiency of trials. Together, big technology providers and pharmaceutical start-ups are setting the course for more effective clinical trials in the future. Key Issues Addressed
Key Topics Covered: 1. Strategic Imperatives 2. Growth Opportunity Analysis
3. Use Case-Clinical Trial Design
4. Use Case-Patient Enrichment, Recruitment, and Enrollment
5. Use Case-Patient Monitoring, Medical Adherence, and Retention
6. Use Case-Investigator and Site Selection
7. Other Companies to Watch 8. Growth Opportunity Universe
For more information about this report visit https://www.researchandmarkets.com/r/zfj4zr About ResearchAndMarkets.com Media Contact: Research and Markets Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg View original content:https://www.prnewswire.com/news-releases/growth-opportunities-and-innovative-use-cases-for-ai-in-clinical-trials-2022-remote-recruitment-to-expand-patient-diversity-for-cancer-trials-301732277.html SOURCE Research and Markets |
||
|
||
Copyright 2023 PR Newswire Association LLC. | Back to overview list |